Andrew N. Schiff, Director at Aclaris Therapeutics, Inc. (ACRS), sold 104,074 shares at $16.89 ($1.7M) on 2022-10-18, disclosed to the SEC on 2022-10-19.
Open-market sale of $1.7M ACRS by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $16.05 | 19,944 | $320K | 18.6% |
| 2 | $16.05 | 19,944 | $320K | 18.6% |
| 3 | $16.89 | 32,093 | $542K | 31.4% |
| 4 | $16.89 | 32,093 | $542K | 31.4% |
| Total | $16.57 avg | 104,074 | $1.7M | 100% |
| Filing → |
| ACRS | SELL | 2022-10-11 | $237K | — | Filing → |
| ACRS | SELL | 2022-10-06 | $1.5M | — | Filing → |
| ACRS | SELL | 2022-06-21 | $592K | — | Filing → |